BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 19574470)

  • 1. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
    Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
    J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
    Brauch H; Schroth W; Eichelbaum M; Schwab M; Harbeck N;
    Breast Care (Basel); 2008; 3(1):43-50. PubMed ID: 20824020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
    Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
    Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
    Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
    Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
    Barrière J; Formento JL; Milano G; Ferrero JM
    Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
    Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Suc E; Sillet-Bach I; Filleron T; Roché H; Chatelut E; White-Koning M; Thomas F
    Clin Pharmacol Ther; 2019 Sep; 106(3):585-595. PubMed ID: 30786012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
    Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
    J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of endocrine therapy in breast cancer.
    Weinshilboum R
    Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
    Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
    J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
    Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.